The CIBI platform aims to identify, characterise and valorise the therapeutic potential of new bioactive compounds involved in various pathologies.
To achieve these objectives, complementary approaches have been developed that allow us to master the different steps from the identification of active molecules (HTS screening), through in vitro and in cellulo validation to the in ovo evaluation of their activities (hit to lead).
The way the CIBI platform operates and its resources allow us to offer different types of services: i) a complete service provided by CIBI engineers, 2) access to certain equipment (e.g. robotics), iii) the development of collaborative scientific projects, iv) the establishment of partnerships with industry.
CIBI is now an integral part of C@PS, a platform that brings together all the screening activities on the Saclay plateau under a single banner, which was awarded the IBISA label at the end of 2018.)
C@PS combines the skills of i) the CCCHD platform (Joliot, CEA, Saclay) for high-throughput biological screening and the preparation of targeted chemical libraries, ii) the CIBLOT platform (Faculty of Pharmacy, Université Paris sud, Châtenay-Malabry) for the measurement of protein/ligand interactions by alpha-screen technology and the quantification of cellular parameters, iii) the CTPF platform (ICSN, CNRS, Gif-sur-Yvette) for the measurement of protein/ligand interactions by thermal shift assay and the analysis of transcriptomes by quantitative PCR and iv) the CIBI platform (ICSN, CNRS, Gif-sur-Yvette). The latter combines the equipment necessary for carrying out high-throughput biological screening. It also studies the mode of action of the most promising active compounds ("hits").
Lab of attachment
1, avenue de la Terrasse
ICSN, CNRS-UPR 2301